| Literature DB >> 35041776 |
Lisa L Abuogi1,2, Maricianah Onono3, Thomas A Odeny3,4, Kevin Owuor3,5, Anna Helova6, Karen Hampanda2,7, Tobias Odwar3, Dickens Onyango8, Leslie A McClure9, Elizabeth A Bukusi3, Janet M Turan6.
Abstract
INTRODUCTION: Retention in HIV care and adherence to antiretroviral therapy (ART) during pregnancy and postpartum for women living with HIV (WLWH) are necessary to optimize health outcomes for women and infants. The objective of this study was to evaluate the impact of two evidenced-based behavioural interventions on postpartum adherence and retention in WLWH in Kenya.Entities:
Keywords: PMTCT; postpartum; retention; viral suppression; women living with HIV
Mesh:
Substances:
Year: 2022 PMID: 35041776 PMCID: PMC8765560 DOI: 10.1002/jia2.25852
Source DB: PubMed Journal: J Int AIDS Soc ISSN: 1758-2652 Impact factor: 5.396
Figure 1MOTIVATE study population.
Baseline characteristics of pregnant women living with HIV on ART enrolling into the MOTIVATE study by study arm
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
| Total |
|
|
|
|
|
|
| Enrolment age years | 0.839 | |||||
| Mean (SD) | 28.8 (5.5) | 28.0 (5.4) | 28.3 (5.5) | 28.9 (5.8) | 28.5 (5.6) | |
| Enrolment age (years) | 0.978 | |||||
| <25 years | 80 (24.0) | 101 (30.2) | 92 (27.9) | 88 (26.3) | 361 (27.1) | |
| 25–28 years | 86 (25.8) | 77 (23.1) | 76 (23.0) | 78 (23.4) | 317 (23.8) | |
| 29–32 years | 83 (24.9) | 84 (25.1) | 85 (25.8) | 78 (23.4) | 330 (24.8) | |
| 33+ years | 84 (25.2) | 72 (21.6) | 77 (23.3) | 90 (26.9) | 323 (24.3) | |
| Marital status | 0.640 | |||||
| Married | 308 (92.5) | 306 (91.6) | 287 (87.0) | 317 (94.9) | 1218 (91.5) | |
| Widowed | 9 (2.7) | 11 (3.3) | 12 (3.6) | 4 (1.2) | 36 (2.7) | |
| Single | 14 (4.2) | 13 (3.9) | 25 (7.6) | 10 (3.0) | 62 (4.7) | |
| Divorce | 1 (0.3) | 1 (0.3) | 1 (0.3) | 2 (0.6) | 5 (0.4) | |
| Separated | 1 (0.3) | 3 (0.9) | 5 (1.5) | 1 (0.3) | 10 (0.8) | |
| Gestational period (weeks) | 0.143 | |||||
| Median (IQR) | 26.0 (20.0–30.0) | 26.0 (20.0–30.0) | 24.0 (19.0–28.0) | 24.0 (16.0–28.0) | 24.0 (20.0–30.0) | |
| Gravida | 0.050 | |||||
| 1 | 31 (9.3) | 26 (7.8) | 34 (10.3) | 16 (4.8) | 107 (8.0) | |
| ≥2 | 302 (90.7) | 308 (92.2) | 296 (89.7) | 318 (95.2) | 1224 (92.0) | |
| HIV status at time of pregnancy | 0.122 | |||||
| Known positive | 257 (77.2) | 248 (74.3) | 251 (76.1) | 293 (87.7) | 1049 (78.8) | |
| New diagnosis | 76 (22.8) | 86 (25.7) | 79 (23.9) | 41 (12.3) | 282 (21.2) | |
| ART regimen | 0.475 | |||||
| PI‐based | 13 (3.9) | 23 (6.9) | 11 (3.3) | 14 (4.2) | 61 (4.6) | |
| NNRTI‐based | 320 (96.1) | 311 (93.1) | 319 (96.7) | 320 (95.8) | 1270 (95.4) | |
| Baseline ART adherencea | 0.695 | |||||
| Fair/poor ( | 14 (4.2) | 7 (2.1) | 8 (2.4) | 6 (1.8) | 35 (2.6) | |
| Good ( | 267 (80.2) | 256 (76.6) | 246 (74.5) | 294 (88.0) | 1063 (79.9) | |
| Missing | 52 (15.6) | 71 (21.3) | 76 (23.0) | 34 (10.2) | 233 (17.5) | |
| Time on ART (months) | 0.073 | |||||
| Median (IQR) | 17.0 (3.0–41.0) | 11.0 (1.0–33.0) | 17.0 (2.0–35.0) | 29.0 (9.0–50.0) | 18.0 (2.0–40.0) | |
| Baseline CD4 counta | 0.824 | |||||
| Median (IQR) | 520.0 (383.5–637.5) | 480.5 (270.5–721.5) | 499.0 (369.0–648.0) | 536.0 (391.0–674.0) | 516.5 (348.5–667.5) | |
| Baseline viral loada | 0.900 | |||||
| Undetectable | 148 (44.4) | 150 (44.9) | 148 (44.8) | 172 (51.5) | 618 (46.4) | |
| <1000 copiesb | 55 (16.5) | 22 (6.6) | 31 (9.4) | 26 (7.8) | 134 (10.1) | |
| ≥1000 copies | 20 (6.0) | 19 (5.7) | 16 (4.8) | 15 (4.5) | 70 (5.3) | |
| Missing | 110 (33.0) | 143 (42.8) | 135 (40.9) | 121 (36.2) | 509 (38.2) | |
| Baseline WHO Stage | 0.985 | |||||
| WHO Stage I | 213 (64.0) | 223 (66.8) | 198 (60.0) | 182 (54.5) | 816 (61.3) | |
| WHO Stage II | 82 (24.6) | 75 (22.5) | 97 (29.4) | 112 (33.5) | 366 (27.5) | |
| WHO Stage III | 31 (9.3) | 31 (9.3) | 32 (9.7) | 35 (10.5) | 129 (9.7) | |
| WHO Stage IV | 6 (1.8) | 5 (1.5) | 3 (0.9) | 5 (1.5) | 19 (1.4) | |
Abbreviations: ART, antiretroviral treatment; CMM, community mentor mother; IQR, interquartile range; NNRTI, non‐nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SD, standard deviation; WHO, World Health Organization.
a Within 3 months of study enrolment.
bDoes not include undetectable viral loads.
Comparison of retention and adherence at 12 months postpartum by study arm
| Outcome |
|
| Risk ratio (95% confidence interval) |
|
|---|---|---|---|---|
| Retention | 1331 | |||
| Control | 253 (76.0) | Reference | ||
| Text message only | 263 (78.7) | 1.08 (0.97–1.21) | 0.141 | |
| CMM only | 262 (79.4) | 1.06 (0.96–1.17) | 0.248 | |
| CMM and text message | 264 (79.0) | 1.04 (0.94–1.15) | 0.460 | |
| Self‐reported ART good adherence | 1041 | |||
| Control | 247 (97.6) | Reference | ||
| Text message only | 258 (98.5) | 1.01 (0.99–1.03) | 0.387 | |
| CMM only | 253 (96.6) | 0.99 (0.95–1.03) | 0.554 | |
| CMM and text message | 255 (96.6) | 0.99 (0.94–1.04) | 0.664 |
Abbreviations: ART, antiretroviral treatment; CMM, community mentor mother.
Adjusted for age and gravidity.
Not adjusted for age and gravidity due to nonconvergence.
Comparison of baseline characteristics by HIV care engagement and viral load outcomes at 12 months postpartum
| Retention in care | Viral suppression | |||||||
|---|---|---|---|---|---|---|---|---|
| Total | Retained ( | Lost to follow up ( |
| Total | >1000 copies/ml ( | ≤1000 copies/ml ( |
| |
| Enrolment age (years) | <0.001 | 0.7429 | ||||||
| <25 | 361 | 316 (25.6) | 45 (46.9) | 201 | 11 (25.6) | 190 (25.4) | ||
| 25–28 | 317 | 292 (23.6) | 25 (26.0) | 184 | 8 (18.6) | 176 (23.5) | ||
| 29–32 | 330 | 310 (25.1) | 20 (20.8) | 209 | 14 (32.6) | 195 (26.1) | ||
| ≥33 | 323 | 317 (25.7) | 6 (6.2) | 197 | 10 (23.3) | 187 (25.0) | ||
| Marital status | 0.011 | 0.933 | ||||||
| Married | 1218 | 1134 (91.8) | 84 (87.5) | 734 | 40 (93.0) | 694 (92.8) | ||
| Not married | 113 | 101 (8.2) | 12 (12.5) | 57 | 3 (7.0) | 54 (7.2) | ||
| Gravidity | 0.016 | 0.016 | ||||||
| 1 | 107 | 93 (7.5) | 14 (14.6) | 53 | 3 (7.0) | 50 (6.7) | ||
| ≥2 | 1224 | 1142 (92.5) | 82 (85.4) | 738 | 40 (93.0) | 698 (93.3) | ||
| HIV status at pregnancy | <0.001 | 0.692 | ||||||
| Known positive | 1049 | 1004 (81.3) | 45 (46.9) | 630 | 35 (81.4) | 595 (79.5) | ||
| Newly positive | 282 | 231 (18.7) | 51 (53.1) | 161 | 8 (18.6) | 153 (20.5) | ||
| ART regimen | 0.229 | 0.372 | ||||||
| PI‐based | 61 | 59 (4.8) | 2 (2.1) | 38 | 3 (7.0) | 35 (4.7) | ||
| NNRTI‐based | 1270 | 1176 (95.2) | 94 (97.9) | 753 | 40 (93.0) | 713 (95.3) | ||
| Baseline adherence | <0.001 | 0.040 | ||||||
| Fair/poor | 35 | 29 (2.4) | 6 (6.3) | 20 | 3 (7.0) | 17 (2.3) | ||
| Good | 1063 | 1019 (82.5) | 44 (46.3) | 648 | 31 (72.1) | 617 (82.5) | ||
| Missing | 232 | 187 (15.1) | 45 (47.4) | 123 | 9 (20.9) | 114 (15.2) | ||
| Baseline viral load | 1128 | 0.763 | <0.001 | |||||
| < 1000 copies/ml | 999 | 957 (88.6) | 42 (87.5) | 614 | 18 (50.0) | 596 (91.6) | ||
| ≥1000 copies/ml | 129 | 123 (11.4) | 6 (12.5) | 73 | 18 (50.0) | 55 (8.4) | ||
Abbreviations: NNRTI, non‐nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Figure 2Competing risks regression model of cumulative incidence of proportion of women lost to follow up from delivery to 12 months postpartum by study arm.
Per‐protocol analysis comparing retention at 12 months postpartum by study arm in women who received at least 80% of the expected study intervention
| Outcome Retention | Overall retention | Retention if ≥80% of intervention received | Risk ratio (95% confidence interval) |
|
|---|---|---|---|---|
| Control | 253 (76.0) | 253 (76.0) | Reference | |
| Text message only | 263 (78.7) | 138 (93.9) | 1.24 (1.16–1.32) | <0.001 |
| CMM only | 262 (79.4) | 165 (97.6) | 1.29 (1.21–1.37) | <0.001 |
| CMM and text message | 264 (79.0) | 94 (97.9) | 1.29 (1.21–1.37) | <0.001 |
Abbreviation: CMM, community mentor mother.